Skip to content

Author

Yin-Huang Gao

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Reversal of acquired osimertinib resistance by YAP inhibition in lung cancer is associated with lipid metabolic reprogramming.

Osimertinib (Osi), as the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has demonstrated remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC). However, recent studies have found that its acquired resistance severely limits its therapeutic effect. This stud...

Jun-Yuan Huang, Yin-Huang Gao, Shi-Qin Jiang et al. · 0 citations
Review Open access Aug 2026

The Crosstalk Between YAP/TAZ and Cancer Metabolism: From Mechanistic Insights to Drug Discovery

The interplay between YAP/TAZ and metabolic reprogramming in cancer is systematically clarified, the core molecular networks through which YAP/TAZ govern each metabolic pathway are delineated, and the current pharmacological inhibitors targeting YAP/TAZ-regulated metabolic networks are summarized.

Yin-Huang Gao, Ming-Hong Chen, Song-Xia Lin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.